Many of the structural features of early diabetic kidney disease (DKD) were diminished in the group treated with SGLT2 inhibitors along with cellular transcriptional profiles across nephron segments, reflecting restoration of metabolic perturbations toward normal. This evidence concerns the gene SLC5A2 and diabetic kidney disease.